Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 91.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,250 shares of the company's stock after selling 13,750 shares during the period. Harel Insurance Investments & Financial Services Ltd.'s holdings in Moderna were worth $35,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in MRNA. US Bancorp DE boosted its holdings in Moderna by 13.2% in the fourth quarter. US Bancorp DE now owns 16,962 shares of the company's stock worth $705,000 after acquiring an additional 1,981 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Moderna by 113.3% in the fourth quarter. Jones Financial Companies Lllp now owns 14,841 shares of the company's stock worth $617,000 after buying an additional 7,883 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Moderna by 9.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after buying an additional 211,426 shares in the last quarter. M&T Bank Corp grew its holdings in shares of Moderna by 10.1% during the fourth quarter. M&T Bank Corp now owns 17,759 shares of the company's stock valued at $739,000 after buying an additional 1,622 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its position in shares of Moderna by 4,418.9% during the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock valued at $6,127,000 after acquiring an additional 144,099 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.59 during mid-day trading on Monday, reaching $29.90. The company's stock had a trading volume of 8,212,025 shares, compared to its average volume of 8,714,063. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $129.39. The stock has a fifty day moving average of $26.77 and a two-hundred day moving average of $31.28.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the prior year, the company posted ($3.07) EPS. The firm's revenue for the quarter was down 35.3% on a year-over-year basis. As a group, equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. Morgan Stanley reduced their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Barclays decreased their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Citigroup initiated coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Royal Bank Of Canada cut their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Finally, UBS Group dropped their target price on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus price target of $46.61.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.